Clinical Trial Update: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial evaluating the safety, tolerability, and efficacy of AZD2373 in participants with APOL1-mediated kidney disease is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apol1-mediated Kidney Disease

Drugs mentioned

• AZD2373

Snippet

Sponsor: AstraZeneca | Conditions: APOL1-Mediated Kidney Disease | Phase 2 | Status: RECRUITING